Hester Biosciences Reports Strong Financial Performance in Q3 2024

Hester Biosciences, a smallcap pharmaceutical company, has recently announced its financial results for the quarter ending September 2024. The company has shown a very positive performance in this quarter, with a significant improvement in its financial score from 9 to 27 in the last three months.

One of the key highlights of the financials is the growth in Profit Before Tax (PBT) less Other Income, which has increased by 317.92% year on year. The company has also seen a growth of 100.5% in Profit After Tax (PAT) compared to the same quarter last year. This trend is expected to continue in the near term.

Hester Bios has also shown a strong operating cash flow, with the highest amount of Rs 48.13 crore generated in the last three years. The company has also been able to reduce its debt and maintain a low Debt-Equity Ratio of 0.81 times.

Another positive aspect of the financials is the increase in Inventory Turnover Ratio, which indicates that the company has been able to sell its inventory at a faster rate. The company has also shown a positive trend in Net Sales and Operating Profit (PBDIT) in the last five quarters.

On the other hand, the rising interest cost is a concern for Hester Bios, as it has increased by 38.94% over the preceding nine months period. This could be due to increased borrowings by the company.

Overall, Hester Biosciences has shown a strong financial performance in the quarter ending September 2024. With a positive trend in key financial indicators, the company is expected to continue its growth in the near future. MarketsMOJO has given a 'Hold' call for the stock, indicating a neutral stance for investors.